After Gilead (GILD) announced that the FDA had put ongoing GS-4182+GS-1720 combination trials on clinical hold after the observance of decreased lymphocyte counts in some patients, Oppenheimer called the combination “the vanguard of Gilead’s efforts to evergreen the BIKTARVY franchise.” Without further details, the firm can’t rule out some sort of class effect for the combination, but it is “not sounding the alarm just yet” as the company “has a track record of resiliency in HIV drug development,” says the analyst, who reiterates an Outperform rating on Gilead shares.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GILD:
- Citi sees Gilead clinical holds as only ‘minor setback’
- Gilead weekly oral hold should not affect lenacapavir PDUFA, says RBC Capital
- FDA placed clinical hold on Gilead HIV treatment trials of GS-1720
- Gilead down 2% to $111.14 after FDA placed hold on some HIV trials
- Gilead Sciences: Strong Market Position and Growth Potential Drive Buy Rating
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue